Search clinical trials for: Afuresertib

Total 15 results

GlaxoSmithKline

Completed

Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers

Cancer

Australia
Novartis Pharmaceuticals

Completed

Continuation Study of the Oral AKT Inhibitor GSK2110183

Cancer

Australia, United States, Ireland, Canada, Korea, Republic of
Novartis Pharmaceuticals

Terminated

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

Neoplasms, Haematologic

Japan
Novartis
Amgen

Terminated

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Cancer

United States
Laekna Limited

Completed

Human Mass Balance and Biotransformation Study of [14C]Afuresertib

Healthy Volunteer

China
Laekna Limited

Active, not recruiting

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Metastatic Castration-resistant Prostate Cancer

United States, Korea, Republic of
Sahlgrenska University Hospital, Sweden

Completed

Heart and Renal Failure in Hip Fracture Surgery

Renal Insufficiency | Hip Fractures | Hypotension | Heart Injuries

Sweden
Novartis Pharmaceuticals

Completed

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

Cancer

Taiwan, Korea, Republic of
Laekna LLC

Active, not recruiting

Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Breast Cancer

United States, China
Laekna Limited

Active, not recruiting

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II)

Platinum-resistant Ovarian Cancer

United States, China
Laekna Limited

Recruiting

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Cervical Cancer | Esophageal Cancer | NSCLC | Solid Tumor | Endometrial Cancer | Gastric and Gastroesophageal Junction Adenocarcinoma

China
GlaxoSmithKline

Withdrawn

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

Cancer
Laekna Limited

Completed

PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

Solid Tumor | TNBC - Triple-Negative Breast Cancer

China
Portola Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

Germany
Chang Gung Memorial Hospital

Recruiting

Risk of Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy

Acute Kidney Injury

Taiwan

3

Subscribe